Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms
- 31 July 2006
- journal article
- case report
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 102 (1), 5-7
- https://doi.org/10.1016/j.ygyno.2006.03.048
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerGynecologic Oncology, 2005
- VEGF-Targeted Therapy in Metastatic Renal Cell CarcinomaThe Oncologist, 2005
- Survival among women with borderline ovarian tumors and ovarian carcinomaCancer, 2004
- Noninvasive and Invasive Micropapillary (Low-Grade) Serous Carcinoma of the OvaryThe American Journal of Surgical Pathology, 2003
- Micropapillary Serous Ovarian Carcinoma: Surgical Management and Clinical OutcomeGynecologic Oncology, 2002
- Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors)Cancer, 2002
- Vascular Endothelial Growth Factor Expression in Serous Ovarian Carcinoma: Relationship with High Mitotic Activity and High FIGO StageGynecologic Oncology, 2002
- Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potentialPublished by Ovid Technologies (Wolters Kluwer Health) ,2002
- Toward the Development of a Universal Grading System for Ovarian Epithelial Carcinoma: I. Prognostic Significance of Histopathologic Features—Problems Involved in the Architectural Grading SystemGynecologic Oncology, 1998
- Toward the development of a universal grading system for ovarian epithelial carcinomaCancer, 1998